Literature DB >> 16518436

Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.

Vicki L Fisher1, Yvonne J Barnes, Suzanne L Nuss.   

Abstract

PURPOSE/
OBJECTIVES: To provide clinical insights into dosing and administration of IV busulfan, a conditioning agent for hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Review of published literature related to busulfan pretransplant conditioning using MEDLINE. Meeting abstracts, investigational protocols, and pharmaceutical manufacturers' package inserts also were reviewed. DATA SYNTHESIS: Busulfan is an effective myeloablative conditioning agent for HSCT. The IV formulation increases dose assurance and the ability to target a therapeutic window. Therapeutic drug monitoring ensures that targeted blood levels are achieved, especially in children, thereby preventing underdosing, which can lead to disease progression or rejection, as well as overdosing, which can cause an increased risk of toxic side effects.
CONCLUSIONS: IV busulfan is a convenient, safe, and effective conditioning agent used in HSCT that has a predictable pharmacokinetic profile. IMPLICATIONS FOR NURSING: An understanding of the pharmacokinetic principles underlying the relationship between the therapeutic window for busulfan and optimal HSCT outcomes will facilitate proper dosing and administration of IV busulfan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518436     DOI: 10.1188/06.ONF.E36-E43

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  2 in total

1.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells.

Authors:  Lesley J Scott; Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.